An Easy-To-Use Survival Score Compared to Existing Tools for Older Patients with Cerebral Metastases from Colorectal Cancer

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2020 Apr 3

PMID 32235637

Citations 2

Authors

Dirk Rades

Trang Nguyen

Stefan Janssen

Steven E Schild

Affiliations

Soon will be listed here.

Abstract

An easy-to-use survival score was developed specifically for older patients with cerebral metastases from colorectal cancer, and was compared to existing tools regarding the accuracy of identifying patients who die in ≤6 months and those who survive for ≥6 months. The new score was built from 57 patients receiving whole-brain irradiation. It included three groups identified from 6-month survival rates based on two independent predictors (performance status and absence/presence of non-cerebral metastases), with 6-month survival rates of 0% (0 points), 26% (1 point), and 75% (2 points), respectively. This score was compared to diagnosis-specific scores, namely the diagnosis-specific graded prognostic assessment (DS-GPA), the Dziggel-Score and the WBRT-30-CRC (whole-brain radiotherapy with 30 Gy in 10 fractions for cerebral metastases from colorectal cancer) score and to a non-diagnosis-specific score for older persons (Evers-Score). Positive predictive values were 100% (new score), 87% (DS-GPA), 86% (Dziggel-Score), 91% (WBRT-30-CRC), and 100% (Evers-Score), respectively, for patients dying ≤6 months, and 75%, 33%, 75%, 60%, and 45%, respectively, for survivors ≥6 months. Of the five tools, the new score and the Evers-Score were most precise in identifying patients dying ≤6 months. The new score and the Dziggel-Scores were best at identifying patients surviving ≥6 months. When combining the results, the new score appeared preferable to the existing tools. The score appears not necessary for patients with additional liver metastases, since their 6-month survival rate was 0%.

Citing Articles

Metastatic Colorectal Cancer.

Passardi A, Marisi G, Ulivi P Cancers (Basel). 2021; 13(24).

PMID: 34944966 PMC: 8699712. DOI: 10.3390/cancers13246346.

Brain Metastases from Colorectal Cancer: A Systematic Review of the Literature and Meta-Analysis to Establish a Guideline for Daily Treatment.

Muller S, Kohler F, Hendricks A, Kastner C, Borner K, Diers J Cancers (Basel). 2021; 13(4).

PMID: 33669974 PMC: 7924831. DOI: 10.3390/cancers13040900.

References

Evers J, Schild S, Segedin B, Nagy V, Khoa M, Trang N . A new score predicting survival prognosis after whole-brain radiotherapy alone for brain metastases in elderly patients. Anticancer Res. 2014; 34(5):2455-8. View

Rades D, Sehmisch L, Bajrovic A, Janssen S, Schild S . Comparison of 20×2 Gy and 12×3 Gy for Whole-brain Irradiation of Multiple Brain Metastases from Malignant Melanoma. In Vivo. 2016; 30(6):917-919. DOI: 10.21873/invivo.11013. View

Schouten L, Rutten J, Huveneers H, Twijnstra A . Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer. 2002; 94(10):2698-705. DOI: 10.1002/cncr.10541. View

Rawla P, Sunkara T, Barsouk A . Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors. Prz Gastroenterol. 2019; 14(2):89-103. PMC: 6791134. DOI: 10.5114/pg.2018.81072. View

Keum N, Giovannucci E . Global burden of colorectal cancer: emerging trends, risk factors and prevention strategies. Nat Rev Gastroenterol Hepatol. 2019; 16(12):713-732. DOI: 10.1038/s41575-019-0189-8. View

Araghi M, Soerjomataram I, Jenkins M, Brierley J, Morris E, Bray F . Global trends in colorectal cancer mortality: projections to the year 2035. Int J Cancer. 2018; 144(12):2992-3000. DOI: 10.1002/ijc.32055. View

Rades D, Panzner A, Dziggel L, Haatanen T, Lohynska R, Schild S . Dose-escalation of whole-brain radiotherapy for brain metastasis in patients with a favorable survival prognosis. Cancer. 2011; 118(15):3852-9. DOI: 10.1002/cncr.26680. View

Barnholtz-Sloan J, Sloan A, Davis F, Vigneau F, Lai P, Sawaya R . Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol. 2004; 22(14):2865-72. DOI: 10.1200/JCO.2004.12.149. View

Sperduto P, Chao S, Sneed P, Luo X, Suh J, Roberge D . Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients. Int J Radiat Oncol Biol Phys. 2009; 77(3):655-61. DOI: 10.1016/j.ijrobp.2009.08.025. View

10.

Rades D, Hansen H, Janssen S, Schild S . Diagnosis-specific WBRT-30-CRC Score for Estimating Survival of Patients Irradiated for Brain Metastases from Colorectal Cancer. Anticancer Res. 2019; 39(5):2569-2574. DOI: 10.21873/anticanres.13379. View

11.

Tsao M, Rades D, Wirth A, Lo S, Danielson B, Gaspar L . Radiotherapeutic and surgical management for newly diagnosed brain metastasis(es): An American Society for Radiation Oncology evidence-based guideline. Pract Radiat Oncol. 2015; 2(3):210-225. PMC: 3808749. DOI: 10.1016/j.prro.2011.12.004. View

12.

Brown P, Pugh S, Laack N, Wefel J, Khuntia D, Meyers C . Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial. Neuro Oncol. 2013; 15(10):1429-37. PMC: 3779047. DOI: 10.1093/neuonc/not114. View

13.

Gondi V, Pugh S, Tome W, Caine C, Corn B, Kanner A . Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933): a phase II multi-institutional trial. J Clin Oncol. 2014; 32(34):3810-6. PMC: 4239303. DOI: 10.1200/JCO.2014.57.2909. View

14.

Sperduto P, Kased N, Roberge D, Xu Z, Shanley R, Luo X . Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol. 2011; 30(4):419-25. PMC: 3269967. DOI: 10.1200/JCO.2011.38.0527. View

15.

Charlson M, Pompei P, Ales K, MacKenzie C . A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40(5):373-83. DOI: 10.1016/0021-9681(87)90171-8. View

16.

Imaizumi J, Shida D, Narita Y, Miyakita Y, Tanabe T, Takashima A . Prognostic factors of brain metastases from colorectal cancer. BMC Cancer. 2019; 19(1):755. PMC: 6670227. DOI: 10.1186/s12885-019-5973-x. View

17.

Brown P, Gondi V, Pugh S, Tome W, Wefel J, Armstrong T . Hippocampal Avoidance During Whole-Brain Radiotherapy Plus Memantine for Patients With Brain Metastases: Phase III Trial NRG Oncology CC001. J Clin Oncol. 2020; 38(10):1019-1029. PMC: 7106984. DOI: 10.1200/JCO.19.02767. View

18.

Dziggel L, Segedin B, Podvrsnik N, Oblak I, Schild S, Rades D . A survival score for patients with brain metastases from less radiosensitive tumors treated with whole-brain radiotherapy alone. Strahlenther Onkol. 2013; 190(1):54-8. DOI: 10.1007/s00066-013-0394-2. View

19.

Mulvenna P, Nankivell M, Barton R, Faivre-Finn C, Wilson P, McColl E . Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3,.... Lancet. 2016; 388(10055):2004-2014. PMC: 5082599. DOI: 10.1016/S0140-6736(16)30825-X. View

20.

Rades D, Kieckebusch S, Lohynska R, Veninga T, Stalpers L, Dunst J . Reduction of overall treatment time in patients irradiated for more than three brain metastases. Int J Radiat Oncol Biol Phys. 2007; 69(5):1509-13. DOI: 10.1016/j.ijrobp.2007.05.014. View